ARMO BioSciences - Ownership and Business Overview

Life ScienceCompany

ARMO BioSciences Ownership

Who owns ARMO BioSciences?

ARMO BioSciences is owned by Eli Lilly. It was acquired on May 10, 2018.

ARMO BioSciences Business Overview

Where is ARMO BioSciences headquartered?

ARMO BioSciences is headquartered in Redwood City, California.

What sector is ARMO BioSciences in?

ARMO BioSciences is a life science company.

When was ARMO BioSciences founded?

ARMO BioSciences was founded in 2012.

Life Science M&A Summary in 2018

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2018. The largest life science acquisition in 2018 was Shire - which was acquired by Takeda Pharmaceutical for $67.7B.

Join Mergr to view all 246 acquisitions of life science companies in 2018, including 44 acquisitions by private equity firms, and 202 by strategics.

ARMO BioSciences, Inc.

575 Chesapeake Drive,
Redwood City, California 94063
United States,
www.armobio.com

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients, as well as earlier-Phase trials in lung cancer, liver cancer, melanoma and other solid tumor types. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).


 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.